By proceeding, you agree to our Terms of Use and Privacy Policy.
The 2nd Digital Biomarkers & Clinical Measures in Neuro Summit is a groundbreaking event that is set to drive the digital revolution in the field of objective, sensitive, and non-invasive measures in Central Nervous System (CNS) research. With three days of engaging and informative sessions, this summit is a must-attend for professionals in the biopharmaceutical industry who are focused on innovation, validation, and acceptance of digital biomarkers endpoints in CNS pipelines.Featuring over 80 digital health and CNS clinical development experts, this summit aims to address the crucial aspects of standardization and regulatory acceptance of digital tools and data analysis as endpoints in complex neurological indications. Attendees will have the opportunity to discover novel innovations in objective, sensitive, and non-invasive neurological measures, as well as explore emerging digital technologies to enhance internal confidence and scalability.What sets the 2023 edition apart is the inclusion of brand-new presenting pharma companies such as Regeneron, Lundbeck, AbbVie, Pfizer, and Servier. These industry leaders will share their latest advancements in developing novel digital measures and devices to tackle neurological indications with sensitivity and objectivity.The summit offers an extensive pre-conference workshop program, spanning over 12 hours, with two dedicated streams tailored for data scientists and neurology translational scientists. These interactive sessions provide a unique opportunity to delve deep into the latest innovations in big data analysis, data standardization, regulatory requirements, and industry confidence and scalability.One of the highlights of the event is a patient advocate discussion, where attendees will have the privilege of hearing directly from patients and advocates involved in digital measure clinical research. This session aims to provide valuable insights into the patient perspective on meaningful digital measure development and remote trial participation.By bringing together a diverse group of experts, thought leaders, and stakeholders, the 2nd Digital Biomarkers & Clinical Measures in Neuro Summit promises to shape the future of CNS research by fostering collaboration, advancing digital technologies, and paving the way for the integration of objective, sensitive, and non-invasive measures in neurological studies.
Explore the new developments in digital biomarker endpoints in CNS pipelines.
Deep dive into the latest innovations in big data analysis, data standardization, regulatory requirements, and industry confidence and scalability.
Get engaged in interactive sessions and discussions to discover novel innovations for non-invasive neurological measures and emerging digital technologies.
Hear directly from patients and advocates to understand the patient's perspective on meaningful digital measurement, development and remote trial participation.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
"VivoSense is the world leader in data analysis consulting and software, specializing in wearable sensor physiological monitoring solutions for clinical trials, healthcare research, and consumer wellness.
Red Nucleus is the premier provider of strategic learning, performance, and process solutions exclusively for the life sciences industry.
Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.
Cognivue is a risk assessment test that identifies changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It is the world's first FDA-Cleared computerized test of cognitive function. Cognivue was designed to
Cognivue is a risk assessment test that identifies changes in cognitive function that could be indicative of early dementia or Alzheimer's Disease. It is the world's first FDA-Cleared computerized test of cognitive function. Cognivue was designed to objectively, quantitatively and reliably identify
C. Light is a healthtech company that creates objective digital tools and solutions with the aim to identify neuro-ocular signatures. Our mission is to encode the retina to decode the brain using A(eye).
NeuraLight is an AI-powered digital health company on a mission to transform clinical development, diagnostics, and precision medicine in neurology. Using the power of oculometrics, NeuraLight extracts powerful signals of neurological health from vid
NeuraLight is an AI-powered digital health company on a mission to transform clinical development, diagnostics, and precision medicine in neurology. Using the power of oculometrics, NeuraLight extracts powerful signals of neurological health from video of patients' eye movements, performed during si
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.